These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26366962)

  • 21. Intravenous Lacosamide in refractory nonconvulsive status epilepticus.
    Mnatsakanyan L; Chung JM; Tsimerinov EI; Eliashiv DS
    Seizure; 2012 Apr; 21(3):198-201. PubMed ID: 22244046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures.
    Fountain NB; Krauss G; Isojarvi J; Dilley D; Doty P; Rudd GD
    Epilepsia; 2013 Jan; 54(1):58-65. PubMed ID: 22708895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers.
    Cawello W; Bonn R
    J Clin Pharmacol; 2012 Nov; 52(11):1739-48. PubMed ID: 22162508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive lacosamide--5 years' clinical experience.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Res; 2014 Oct; 108(8):1385-91. PubMed ID: 25064538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
    Cawello W; Rosenkranz B; Schmid B; Wierich W
    Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions--first clinical experience.
    Sattler A; Schaefer M; May TW; Rambeck B; Brandt C
    Epilepsy Res; 2011 Aug; 95(3):207-12. PubMed ID: 21543186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation.
    Novy J; Bartolini E; Bell GS; Duncan JS; Sander JW
    Epilepsy Res; 2013 Sep; 106(1-2):250-6. PubMed ID: 23796862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures.
    García-Morales I; Delgado RT; Falip M; Campos D; García ME; Gil-Nagel A
    Seizure; 2011 Dec; 20(10):801-4. PubMed ID: 21917484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sinus node dysfunction: an adverse effect of lacosamide.
    Chinnasami S; Rathore C; Duncan JS
    Epilepsia; 2013 Jun; 54(6):e90-3. PubMed ID: 23360388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy.
    Grosso S; Parisi P; Spalice A; Verrotti A; Balestri P
    Eur J Paediatr Neurol; 2014 Jan; 18(1):55-9. PubMed ID: 24129195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioequivalence of intravenous and oral formulations of the antiepileptic drug lacosamide.
    Cawello W; Bonn R; Boekens H
    Pharmacology; 2012; 90(1-2):40-6. PubMed ID: 22722651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
    Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment.
    Cawello W; Bökens H; Nickel B; Andreas JO; Halabi A
    Epilepsia; 2013 Jan; 54(1):81-8. PubMed ID: 23148731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?
    Novy J; Patsalos PN; Sander JW; Sisodiya SM
    Epilepsy Behav; 2011 Jan; 20(1):20-3. PubMed ID: 21056937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
    Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
    Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy.
    Pasha I; Kamate M; Didagi SK
    Pediatr Neurol; 2014 Oct; 51(4):509-14. PubMed ID: 25266613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
    Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
    Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute or chronic use of lacosamide does not alter its distribution between serum and cerebrospinal fluid.
    Michelhaugh SK; Basha M; Rhoney DH; Shah AK; Mittal S
    Epilepsia; 2015 Nov; 56(11):1732-7. PubMed ID: 26249845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lacosamide, a newer antiepileptic.
    Patyar S; Medhi B
    Neurosciences (Riyadh); 2010 Jan; 15(1):3-6. PubMed ID: 20677583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers.
    Cawello W; Nickel B; Eggert-Formella A
    J Clin Pharmacol; 2010 Apr; 50(4):459-71. PubMed ID: 19841161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.